FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to medicine, namely to endocrinology, and can be used for treating non-alcoholic liver disease accompanying type 2 diabetes mellitus. The declared preparation Mexicor provides reducing manifestations of cytolysis and cholestasis, decreasing the steatosis index, enables improving metabolic lipid and glycaemic values and reducing insulin resistance. Mexicor is applied in a daily therapeutically effective dose of 100 mg 4 times a day for at least 16 weeks.
EFFECT: high pharmacological activity of Mexicor has been shown by achieving the pronounced and stable elimination of fatty liver disease that enables reducing the length of treatment with no side effects.
2 cl, 2 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF TREATING NON-ALCOHOLIC LIVER DISEASE ACCOMPANYING TYPE 2 DIABETES MELLITUS | 2013 |
|
RU2538221C1 |
| METHOD OF EARLY DIAGNOSIS OF NON-ALCOHOLIC FATTY LIVER DISEASE | 2022 |
|
RU2798723C1 |
| METHOD OF DIAGNOSTICS OF LIVER STEATOSIS | 2017 |
|
RU2648183C1 |
| USING LACTITOL AND AN ORAL DOSAGE FORM FOR TREATING AND PREVENTING NON-ALCOHOLIC FATTY LIVER DISEASE | 2018 |
|
RU2692243C1 |
| METHOD OF TREATING NON-ALCOHOLIC FATTY LIVER DISEASE ACCOMPANYING METABOLIC SYNDROME | 2018 |
|
RU2686042C1 |
| DIFFERENTIAL DIAGNOSTIC TECHNIQUE FOR ALCOHOLIC LIVER DISEASE | 2013 |
|
RU2530646C1 |
| METHOD OF PREDICTING THE EFFECTIVENESS OF LITHOLYSIS IN CHOLELITHIASIS IN COMBINATION WITH NON-ALCOHOLIC FATTY LIVER DISEASE | 2023 |
|
RU2813033C1 |
| METHOD OF TREATING NONALCOHOLIC FATTY LIVER DISEASE WITH USE OF PENTOXIFYLLINE AMPLI-PULSE PHORESIS | 2014 |
|
RU2548775C1 |
| METHOD OF SCREENING STUDY OF RISK OF DEVELOPING LIVER DAMAGE OF DIFFERENT ORIGINS | 2017 |
|
RU2675015C1 |
| METHOD OF TREATING NON-ALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH METABOLIC SYNDROME WITH VITAMIN D DEFICIENCY | 2018 |
|
RU2694842C1 |
